

Anti-B7-H3 Antibody (Enoblituzumab Biosimilar)

Cat. No. AB08


Description	
Reactivities	Human/Cynomolgus
Target	B7-H3
Isotype	Human IgG1-Kappa
Conjugation	Unconjugated
ExpressSystem	HEK293
Applications	ELISA
MolecularWeight	49.5 kDa and 23.5 kDa.
Recommended Dilution Buffer	PBS (pH 7.4), contains no stabilizers or preservatives.
Purification	protein A
Sterility	0.2 µM filtered
Endotoxin	Less than 1 EU per µg by the LAL method.
Purity	> 95% as determined by Bis-Tris PAGE
	> 90% as determined by HPLC

Formulation and Storage	
Formulation	PBS, 10% glycerol (pH 7.4)
Storage	Valid for 12 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Background	
B7-H3, a member of the B7 family of immunomodulatory molecules, is overexpressed in a wide range of solid cancers. B7-H3 binds to activated T cells via an as yet unidentified receptor. In assays using sub-optimal amount so anti-CD3 stimulation, 2IgB7H3 enhances T cell proliferation, T cell interferon-gamma (IFN-gamma) production, and cytotoxic T cells induction.	

Assay Data


Bis-Tris PAGE



Enoblituzumab Biosimilar on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

SEC-HPLC

Assay Data




The purity of Enoblituzumab Biosimilar is greater than 90% as determined by SEC-HPLC.

Assay Data

ELISA Data

Enoblituzumab Biosimilar ELISA
0.1µg Human B7-H3, His Tag Per Well



Immobilized Human B7-H3, His Tag at 1µg/ml (100µl/well) on the plate. Dose response curve for Enoblituzumab Biosimilar with the EC50 of 8.5ng/ml determined by ELISA.